載入中
NASDAQHealthcareMedical - Diagnostics & Research
最新資料
US$43.67
−US$0.35 · -0.80%
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
一般交易時段
US$43.67
−US$0.35 · -0.80%
盤中時間採用ET。市場資料可能有所延遲。
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
日內區間
目前US$43.67
52週區間
目前US$43.67
盤中時間採用ET。市場資料可能有所延遲。
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
日內區間
目前US$43.67
52週區間
目前US$43.67
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5.17億 USD | 4.46億 USD | 3.61億 USD | 2.97億 USD | 2.2億 USD |
| 銷貨成本 | 1.57億 USD | 1.48億 USD | 1.13億 USD | 1.02億 USD | 7440萬 USD |
| 毛利 | 3.6億 USD | 2.98億 USD | 2.48億 USD | 1.95億 USD | 1.45億 USD |
| 研究與開發 | 7081.4萬 USD | 6929.4萬 USD | 5730.5萬 USD | 4060.3萬 USD | 2984.3萬 USD |
| 銷售、一般及管理費用 | 2.11億 USD | 2.06億 USD | 1.84億 USD | 1.74億 USD | 1.81億 USD |
| 營業費用 | 2.86億 USD | 2.82億 USD | 3.34億 USD | 2.36億 USD | 2.27億 USD |
| 利息收入 | — | 1115.4萬 USD | 734.4萬 USD | 197.2萬 USD | 13.5萬 USD |
| 利息支出 | — | 2000 USD | 1.5萬 USD | 19.8萬 USD | 24.1萬 USD |
| 折舊和攤銷 | 2141.5萬 USD | 2345.9萬 USD | 2718.8萬 USD | 2592.8萬 USD | 1959.3萬 USD |
| 營業利益 | 7415萬 USD | 1614.2萬 USD | −8579.5萬 USD | −4108.1萬 USD | −8190.3萬 USD |
| 淨利 | 6635.3萬 USD | 2413.8萬 USD | −7440.4萬 USD | −3656萬 USD | −7556.3萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$57.43
上漲空間 31.51%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.1億0.00%2.3兆 USD0.03%US$380.93-0.17%
State Street SPDR S&P Biotech ETFXBI1.07億1.04%103.03億 USD0.35%US$147.7-2.44%
iShares Russell 2000 ETFIWM9123.63萬0.12%787.4億 USD0.19%US$276.34-0.56%
Vanguard Morningstar Small-Cap ETFVB7924.64萬0.04%1853億 USD0.03%US$287.39-0.27%
First Trust NYSE Arca Biotechnology Index FundFBT7059.81萬2.43%28.91億 USD0.55%US$260.05-1.46%
ARK Genomic Revolution ETFARKG6855.78萬3.33%22.19億 USD0.75%US$48.71-1.56%
ARK Innovation ETFARKK6452.57萬0.99%79.17億 USD0.75%US$87.215-0.91%
Vanguard Morningstar Small-Cap Growth ETFVBK4561.23萬0.10%447億 USD0.05%US$337.91-0.87%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBFirst Trust NYSE Arca Biotechnology Index FundFBTARK Genomic Revolution ETFARKGARK Innovation ETFARKKVanguard Morningstar Small-Cap Growth ETFVBKAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
